key: cord-0955304-vfag3w8a
authors: Prema, Jansi; Muthukumaran, Aarthi; Haridas, Nived; Fernando, Edwin; Seshadri, Jayalakshmi; Kurien, Anila Abraham
title: Two cases of double-positive antineutrophil cytoplasmic antibody and anti-glomerular basement membrane disease following BBV152/Covaxin vaccination
date: 2021-10-13
journal: Kidney Int Rep
DOI: 10.1016/j.ekir.2021.10.004
sha: 7d3d4fc7a408e4f22ab585210c8cca682766a0ed
doc_id: 955304
cord_uid: vfag3w8a

nan

Double positive disease is defined as ANCA vasculitis phenotype on biopsy along with anti-GBM antibody in the serum or anti-GBM phenotype on biopsy with ANCA positivity in the serum. Double seropositive vasculitis following seasonal influenza vaccine administration has been reported. 2 To our knowledge, double-positive ANCA and anti-GBM disease following SARS-CoV-2 vaccination has not been reported previously. Temporal association suggests a possible link between the vaccine administration and the development of vasculitis, though a direct link cannot be established.

BBV152/Covaxin is developed using Whole-Virion Inactivated Vero Cell derived platform technology. It also contains immune-potentiators, known as vaccine adjuvants, which are added to the vaccine to increase and boost its immunogenicity. It has been postulated that molecular mimicry, where a foreign antigen shares structural similarities with self-antigens, could be the cause for the development of the autoimmunity. 3 Vaccine adjuvants can also give rise to post-vaccination adverse reactions known as 'autoimmune syndrome induced by adjuvants. 4 To conclude, clinicians should be aware of the rare possibility of vasculitis being the cause for acute kidney injury requiring renal replacement therapy following SARS-CoV-2 vaccination.

Disclosures: None to disclose

Antineutrophil cytoplasmic autoantibody-associated glomerulonephritis following the Pfizer-BioNTech COVID-19 vaccine

Vaccine: friend or foe? Double seropositive vasculitis following influenza vaccination

Could autoimmunity be induced by vaccination?

On vaccine's adjuvants and autoimmunity: current evidence and future perspectives